NCT02353507
Withdrawn
Phase 4
A Multi-Center, Randomized, Comparison Study of a Chitosan (Opticell Ag+) Silver Dressing and a Sodium Carboxymethylcellulose (Aquacel® Ag+) Silver Dressing on Burn Wounds in Pediatrics and Adults Subjects
Medline Industries0 sitesFebruary 2015
ConditionsBandages
Overview
- Phase
- Phase 4
- Intervention
- Not specified
- Conditions
- Bandages
- Sponsor
- Medline Industries
- Primary Endpoint
- Wound Infection Rates
- Status
- Withdrawn
- Last Updated
- 10 years ago
Overview
Brief Summary
The purpose of this prospective, randomized, comparative multi-center study is to compare the effective management of two silver-based dressings in managing exudative wounds in first and second degree burns.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inpatient status at the site
- •Written consent obtained from the subject
- •Burn injury must have been incurred within 36 hours prior to enrollment.
- •Burn injury must be of superficial partial thickness, mid-dermal partial thickness, or a combination of the two depths
- •Burn injury must exceed 3% total body surface area.
Exclusion Criteria
- •Subject is pregnant.
- •Bone fractures.
- •Inhalation-related trauma.
- •Sensitive and/or allergic to materials containing silver.
- •Burn injury exceeds 40% total body surface area.
- •Burn injury diagnosis indicates deep partial or full thickness wounds.
- •Burn a result of electrical/chemical injury or frostbite.
- •An active agent, such as a topical antimicrobial or an enzymatic debriding agent was previously used to treat the burn injury in question.
Outcomes
Primary Outcomes
Wound Infection Rates
Time Frame: Up to 21 days of use
Days required for wound healing
Time Frame: Up to 21 days of use
Secondary Outcomes
- Pain Levels during Dressing Removal(Up to 21 days)
Similar Trials
Completed
N/A
CellFX Comparison to Cryosurgery in Cutaneous Non-Genital Common WartsWartsWarts HandVerrucaNCT04738734Pulse Biosciences, Inc.150
Active, Not Recruiting
N/A
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Cervical Disc Disease at 2 Contiguous LevelsCervical Disc DiseaseNCT04564885Spineart USA300
Active, Not Recruiting
N/A
A Clinical Trial Comparing the BAGUERA C to the Marketed Mobi-C® for the Treatment of Single Level Cervical Disc DiseaseCervical Disc DiseaseNCT04520776Spineart USA284
Completed
N/A
Cooled Radiofrequency vs. Hyaluronic Acid to Manage Knee PainOsteoarthritis of the KneeNCT03381248Avanos Medical177
Completed
N/A
Comparative Study Between CellFX and Electrodessication in Sebaceous Hyperplasia (SH) LesionsSkin LesionSkin AbnormalitiesSebaceous HyperplasiaNCT04539886Pulse Biosciences, Inc.60